Tove Wästerlid

Om mig
Publikationer
Forskningsbidrag
CV
Populärvetenskap och samverkan

Om mig

Jag är specialistläkare i Hematologi vid Karolinska Universitetssjukhuset samt post-doc i gruppen för cancer epidemiologi på KEP. Jag forskar både
epidemiologiskt och molekylärbiologiskt om lymfom. För mer information om min forskning, publikationer och undervisning se den engelska versionen av den här sidan.

Artiklar

Article: ACTA ONCOLOGICA. 2024;63:164-168

Impact of the COVID-19 pandemic on lymphoma incidence and short-term survival - a Swedish Lymphoma Register Study.

Ekberg S; Molin D; Pahnke S; Bergström F; Brånvall E; Smedby KE; Wästerlid T
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2024;204(3):967-975

Cardiovascular diseases after high-dose chemotherapy and autologous stem cell transplant for lymphoma: A Danish population-based study.

Baech J; Husby S; Trab T; Kragholm K; Brown P; Gørløv JS; Jørgensen JM; Gudbrandsdottir S; Severinsen MT; Grønbaek K; Larsen TS; Wästerlid T; Eloranta S; Smeland KB; Jakobsen LH; El-Galaly TC
Article: HEMASPHERE. 2023;7(3):e838

Survival by First-line Treatment Type and Timing of Progression Among Follicular Lymphoma Patients: A National Population-based Study in Sweden.

Weibull CE; Wästerlid T; Wahlin BE; Andersson P-O; Ekberg S; Lockmer S; Enblad G; Crowther MJ; Kimby E; Smedby KE
Article: AMERICAN JOURNAL OF HEMATOLOGY. 2023;98(1):23-30

Sex differences in lymphoma incidence and mortality by subtype: A population-based study.

Radkiewicz C; Bruchfeld JB; Weibull CE; Jeppesen ML; Frederiksen H; Lambe M; Jakobsen L; El-Galaly TC; Smedby KE; Wästerlid T
Article: FRONTIERS IN ONCOLOGY. 2023;13:1176698

Whole-genome informed circulating tumor DNA analysis by multiplex digital PCR for disease monitoring in B-cell lymphomas: a proof-of-concept study.

Haider Z; Wästerlid T; Spångberg LD; Rabbani L; Jylhä C; Thorvaldsdottir B; Skaftason A; Awier HN; Krstic A; Gellerbring A; Lyander A; Hägglund M; Jeggari A; Rassidakis G; Sonnevi K; Sander B; Rosenquist R; Tham E; Smedby KE
Article: BRITISH JOURNAL OF CANCER. 2022;127(10):1808-1815

Standardised survival probabilities: a useful and informative tool for reporting regression models for survival data.

Syriopoulou E; Wästerlid T; Lambert PC; Andersson TM-L
Journal article: ANNALS OF LYMPHOMA. 2022;0(0):0

Diffuse large B-cell lymphoma among the elderly: a narrative review of current knowledge and future perspectives

Wästerlid T; Murphy S; Villa D; El-Galaly TC
Article: BLOOD ADVANCES. 2022;6(8):2657-2666

Incidence and time trends of second primary malignancies after non-Hodgkin lymphoma: a Swedish population-based study.

Joelsson J; Wästerlid T; Rosenquist R; Jakobsen LH; El-Galaly TC; Smedby KE; Eloranta S
Article: FRONTIERS IN ONCOLOGY. 2022;12:984021

Data-driven support to decision-making in molecular tumour boards for lymphoma: A design science approach.

Rodríguez Ruiz N; Abd Own S; Ekström Smedby K; Eloranta S; Koch S; Wästerlid T; Krstic A; Boman M
Article: EJHAEM. 2021;2(4):774-784

Excellent survival after R-Hyper-CVAD in hospitalized patients with high-risk large B-cell lymphoma: The Karolinska experience.

Sonnevi K; Ljungqvist M; Jóelsson JK; Harrysson S; Wästerlid T; Bernell P; Wahlin BE
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2021;195(4):552-560

Statin use and survival in 16 098 patients with non-Hodgkin lymphoma or chronic lymphocytic leukaemia treated in the rituximab era.

Brånvall E; Ekberg S; Eloranta S; Wästerlid T; Birmann BM; Smedby KE
Article: EJHAEM. 2021;2(3):525-529

Temporary cessation of ibrutinib results in reduced grade 3-4 infections and durable remissions-Interim analysis of an on-off-repeat Phase 1b/2 study in patients with chronic lymphocytic leukemia.

Lundin J; Mulder TA; Kättström M; Wästerlid T; Uddevik A; Mellstedt H; Heimersson K; Hansson L; Palma M; Österborg A
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2021;192(3):551-559

Clinical characteristics and outcomes among 2347 patients aged ≥85 years with major lymphoma subtypes: a Nordic Lymphoma Group study.

Wästerlid T; Oren Gradel K; Eloranta S; Glimelius I; El-Galaly TC; Frederiksen H; Smedby KE
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2021;192(1):75-81

Survival of very elderly patients with diffuse large B-cell lymphoma according to treatment intensity in the immunochemotherapy era: a Swedish Lymphoma Register study.

Sonnevi K; Wästerlid T; Melén CM; Harrysson S; Smedby KE; Wahlin BE
Article: AMERICAN JOURNAL OF HEMATOLOGY. 2020;95(7):740-748

Outcome and determinants of failure to complete primary R-CHOP treatment for reasons other than non-response among patients with diffuse large B-cell lymphoma.

Wästerlid T; Harrysson S; Andersson TM-L; Ekberg S; Enblad G; Andersson P-O; Jerkeman M; Eloranta S; Smedby KE
Article: AMERICAN JOURNAL OF HEMATOLOGY. 2020;95(6):652-661

Statin use is associated with improved survival in multiple myeloma: A Swedish population-based study of 4315 patients.

Brånvall E; Ekberg S; Eloranta S; Wästerlid T; Birmann BM; Smedby KE
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2020;189(4):661-671

Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients.

Jakobsen LH; Ellin F; Smeland KB; Wästerlid T; Christensen JH; Jørgensen JM; Josefsson PL; Øvlisen AK; Holte H; Blaker YN; Grauslund JH; Bjørn J; Molin D; Lagerlöf I; Smedby KE; Colvin K; Thanarajasingam G; Maurer MJ; Habermann TM; Song KW; Zhu KY; Gerrie AS; Cheah CY; El-Galaly TC
Journal article: BLOOD. 2019;134:4113

Inferior Outcomes for Older Patients in the Adolescent and Young Adult (AYA) Population with Burkitt Lymphoma Treated with Intensive Immunochemotherapy: An International Study of 108 Patients

Ellin F; Smeland KB; Wasterlid T; Christensen JH; Jorgensen J; Josefsson PL; Holte H; Blaker YN; Grauslund JH; Bjoern J; Molin D; Lagerlof I; Smedby KEE; Colvin K; Thanarajasingam G; Maurer MJ; Habermann TM; Song K; Zhu KY; Gerrie AS; Cheah CY; El-Galaly TCC; Jakobsen LH
Article: JOURNAL OF INTERNAL MEDICINE. 2019;285(4):455-468

Impact of comorbidity on disease characteristics, treatment intent and outcome in diffuse large B-cell lymphoma: a Swedish lymphoma register study.

Wästerlid T; Mohammadi M; Smedby KE; Glimelius I; Jerkeman M; Bottai M; Eloranta S
Journal article: BLOOD. 2018;132:452

Normalization of Survival and No Relapses after One Year in Adult Burkitt Lymphoma Patients Treated with Intensive Immunochemotherapy: An International Study of 159 Real-World Patients

Jakobsen LH; Ellin F; Smeland KB; Wasterlid T; Christensen JH; Jorgensen J; Josefsson PL; Holte HJ; Blaker YN; Grauslund JH; Bjorn J; Molin D; Lagerlof I; Smedby KE; Colvin K; Thanarajasingam G; Gerrie AS; Cheah CY; El-Galaly TC
Article: HEMATOLOGICAL ONCOLOGY. 2017;35(2):151-157

Impact on survival of addition of etoposide to primary chemotherapy in diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study.

Wästerlid T; Hartman L; Székely E; Jerkeman M
Journal article: BLOOD. 2015;126(23):5039

Frequency and Clinical Implication of SOX11 Expression in Burkitt Lymphoma

Wasterlid T; Nordstrom L; Pedersen M; Norgaard PH; Gang AO; Brown PDN; Jerkeman M; Ek S
Journal article: BLOOD. 2014;124(21):4427

R-CHOEP-14 Is Associated with Superior Overall Survival Compared to R-CHOP-21 and R-CHOP-14 in Patients with DLBCL ≤ 70 Years - a Swedish Lymphoma Registry Population Based Study

Wasterlid T; Szekely E; Hartman LW; Jerkeman M
Journal article: PHYSICS IN MEDICINE AND BIOLOGY. 2014;59(22):7013-7029

Three-dimensional vessel segmentation using a novel combinatory filter framework.

Ding Y; Ward WOC; Wästerlid T; Gowland PA; Peters AM; Yang J; Bai L
Article: ANNALS OF ONCOLOGY. 2013;24(7):1879-1886

Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group.

Wästerlid T; Brown PN; Hagberg O; Hagberg H; Pedersen LM; D'Amore F; Jerkeman M
Article: LEUKEMIA & LYMPHOMA. 2011;52(11):2090-2096

Population based study of prognostic factors and treatment in adult Burkitt lymphoma: a Swedish Lymphoma Registry study.

Wästerlid T; Jonsson B; Hagberg H; Jerkeman M
Visa fler

Alla övriga publikationer

Letter: ACTA ONCOLOGICA. 2023;62(6):560-564

The BioLymph study - implementing precision medicine approaches in lymphoma diagnostics, treatment and follow-up: feasibility and first results.

Smedby KE; Wästerlid T; Tham E; Haider Z; Joelsson J; Thorvaldsdottir B; Krstic A; Wahlin BE; Foroughi-Asl H; Karlsson C; Eloranta S; Saft L; Palma M; Kwiecinska A; Hansson L; Österborg A; Wirta V; Rassidakis G; Sander B; Sonnevi K; Rosenquist R
Conference publication: BLOOD. 2022;140:3620-3621

Treatment Sequencing and Survival in Follicular Lymphoma: A National Population-Based Study

Wasterlid T; Warnqvist A; Weibull CE; Wahlin BE; Andersson P-O; Enblad G; Kimby E; Smedby KE
Review: JOURNAL OF INTERNAL MEDICINE. 2022;292(2):243-261

Application of precision medicine in clinical routine in haematology-Challenges and opportunities.

Wästerlid T; Cavelier L; Haferlach C; Konopleva M; Fröhling S; Östling P; Bullinger L; Fioretos T; Smedby KE
Preprint: RESEARCH SQUARE. 2022

Survival by first-line treatment type and timing of progression among follicular lymphoma patients: A national population-based study in Sweden

Weibull C; Wästerlid T; Wahlin B; Andersson P-OA; Ekberg S; Lockmer S; Enblad G; Crowther M; Kimby E; Smedby KE
Conference publication: BLOOD. 2021;138:4587

Good Outcome after R-Hyper-CVAD/R-MA in High-Risk Aggressive B-Cell Lymphoma: A Single-Center Experience

Sonnevi K; Ljungqvist M; Joelsson JK; Harrysson S; Wasterlid T; Bernell P; Wahlin B
Conference publication: BLOOD. 2021;138:2534

Sex Differences in Lymphoma Incidence and Excess Mortality By Subtype: A Comprehensive National Study

Radkiewicz C; Bruchfeld JB; Weibull C; Lambe M; Jakobsen LH; El-Galaly TC; Smedby KE; Wästerlid T
Letter: BLOOD CANCER JOURNAL. 2021;11(5):100

Real-world data on treatment and outcomes of patients with primary mediastinal large B-cell lymphoma: a Swedish lymphoma register study.

Wästerlid T; Hasselblom S; Joelsson J; Weibull CE; Rassidakis G; Sander B; Smedby KE
Meeting abstract: BLOOD. 2019;134:1618

Encouraging Outcomes with Intensive Chemotherapy for Patients with Primary Mediastinal B-Cell Lymphoma - a Swedish Lymphoma Register Study

Wasterlid T; Rassidakis GZ; Sander B; Smedby KE
Conference publication: BLOOD. 2018;132:571

Clinical Characteristics and Outcomes Among Very Elderly Patients with Major Lymphoma Subtypes: A Nordic Lymphoma Group Study

Wasterlid T; Gradel K; Jerkeman M; Frederiksen H; Smedby KE
Letter: ANNALS OF ONCOLOGY. 2018;29(8):1882-1883

Six cycles of R-CHOP-21 are not inferior to eight cycles for treatment of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Population-based Study.

Wästerlid T; Biccler JL; Brown PN; Bøgsted M; Enblad G; Mészáros Jørgensen J; Christensen JH; Wahlin BE; Smedby KE; El-Galaly TC; Jerkeman M
Letter: LEUKEMIA & LYMPHOMA. 2017;58(7):1760-1763

Frequency and clinical implications of SOX11 expression in Burkitt lymphoma.

Wästerlid T; Nordström L; Freiburghaus C; Pedersen M; Nørgaard P; Gang AO; Brown P; Dictor M; Jerkeman M; Ek S
Conference publication: BLOOD. 2017;130

Six Cycles of R-CHOP-21 Is Non-Inferior to 8 Cycles for Treatment of Diffuse Large B Cell Lymphoma - a Nordic Lymphoma Group Population Based Study

Wasterlid T; Biccler JL; Brown PDN; Christensen JH; Enblad G; Jorgensen JM; Smedby KE; El-Galaly TC; Jerkeman M
Conference publication: HAEMATOLOGICA. 2016;101:403

FREQUENCY AND CLINICAL IMPLICATIONS OF SOX11 EXPRESSION IN BURKITT LYMPHOMA

Wasterlid T; Nordstrom L; Pedersen M; Norgaard P; Gang AO; Brown P; Jerkeman M; Ek S
Conference publication: ANNALS OF ONCOLOGY. 2011;22:190-191

PROPOSAL OF A MODIFIED PROGNOSTIC INDEX FOR ADULT BURKITT LYMPHOMA - A POPULATION BASED SWEDISH LYMPHOMA REGISTRY STUDY

Wasterlid T; Jonsson B; Hagberg H; Jerkeman M

Forskningsbidrag

Epidemiologiska och genetiska studier av lymfom hos äldre för framtida precision i diagnostik och behandling

ALF Region Stockholm (Kliniska postdoktorer)

1 January 2020 - 1 January 2023
Genetic studies and evaluation of cell-free tumour DNA for future diagnostic and therapeutic precision in lymphoma

Åke Olssons stiftelse
Magnus Bergvall Foundation
Genetic studies and evaluation of cell-free tumour DNA for future diagnostic and therapeutic precision in lymphoma

Svenska Läkaresällskapet (SLS Projektanslag) (971438)
Genetic studies and evaluation of cell-free tumour DNA for future diagnostic and therapeutic precision in lymphoma

Jeanssons Stiftelse
Epidemiological studies on elderly patients with lymphoma

Karolinska Institutet Stiftelser och Fonder
Epidemiological and genetic studies on lymphoma for future diagnostic and therapeutic precision

Åke Wibergs Stiftelse
Könsrelaterade skillnader i incidens och överlevnad vid lymfom

Gunnar Grimfors gåvofond
Könsrelaterade skillnader i incidens och överlevnad vid lymfom

Karolinskas fond för leukemiforskning

Anställningar

Anknuten till Forskning, Medicin, Solna, Karolinska Institutet, 2017-2026
ST-läkare Hematologi, Department of Hematology, Karolinska University Hospital, 2017-2023

Handledare

Erik Boberg, 2023
Linn Deleskog Spångberg, 2022
Johanna Borg Bruchfeld, Sex-related differences in incidence and outcomes among patients with lymphoma: epidemiological and biological perspectives, https://ki.se/en/people/johanna-borg-bruchfeld, 2021
Joel Joelsson, 2019

Om mig

Artiklar

Alla övriga publikationer

Forskningsbidrag

Anställningar

Handledare

Nyheter från KI

Kalenderhändelser från KI